Lasofoxifene as a potential treatment for ER plus metastatic breast cancer.

被引：4
|
作者：
Laine, Muriel
Fanning, Sean William
Greene, Marianne
Chang, Ya-fang
Phung, Linda
Tan, Tina T.
Hiipakka, Richard
Komm, Barry
Greene, Geoffrey
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Sermonix, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.1056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1056
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Lasofoxifene decreases breast cancer lung and liver metastasis in a mammary intraductal (MIND) xenograft model of mutant ERα plus breast cancer
    Laine, M.
    Greene, M.
    Chang, Y-F
    Phung, L.
    Hiipakka, R.
    Komm, B.
    Greene, G. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [22] A role for fulvestrant monotherapy in the first-line treatment of ER plus metastatic breast cancer?
    Mahtani, Reshma L.
    BREAST JOURNAL, 2020, 26 (02): : 109 - 111
  • [23] The role of IL-6 in ERα plus breast cancer and potential use for Siltuximab, an anti-IL-6 antibody, in ERα plus breast cancer treatment
    Axel, Amy
    Casneuf, Tineke
    King, Peter
    Alvarez, J. D.
    Hall, Brett
    Sasser, Kate
    CANCER RESEARCH, 2013, 73 (08)
  • [24] Visualizing treatment patterns and survival in metastatic breast cancer.
    Gilbert, Aidan
    Williams, Courtney
    Kandhare, Pravinkumar
    Nakhmani, Arie
    Meersman, Stephen C.
    Garrett-Mayer, Elizabeth
    Kaltenbaugh, Melinda
    Azuero, Andres
    Ingram, Stacey A.
    Burkard, Mark E.
    Bhatia, Smita
    Kenzik, Kelly
    Rocque, Gabrielle Betty
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [25] PALBOCICLIB IN THE TREATMENT OF METASTATIC BREAST CANCER. INSTITUTIONAL EXPERIENCE
    Mainella, A.
    Vigo, S.
    Marmissolle, F.
    Price, P.
    Sansano, M.
    Lujan, M. L.
    Dominguez, M. P.
    Zapata Caamano, G.
    Menna, E.
    Giacomi, N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A624 - A624
  • [26] Treatment of Metastatic Breast Cancer - Breast Cancer as a Chronic Disease: Triple Negative Breast Cancer.
    Stearns, V.
    CANCER RESEARCH, 2011, 71
  • [27] Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
    O'Shaughnessy, Joyce
    Osborne, Cynthia
    Pippen, John E.
    Yoffe, Mark
    Patt, Debra
    Rocha, Christine
    Koo, Ingrid Chou
    Sherman, Barry M.
    Bradley, Charles
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (03): : 205 - 214
  • [28] Efficacy, maximal tolerated dose, and toxicokinetics of TTC-352 in rats and dogs, a partial ER agonist for metastatic ER plus breast cancer.
    Tonetti, Debra A.
    Xiong, Rui
    Zhao, Jiong
    Gutgesell, Lauren
    Dudek, Arkadiusz Z.
    Thatcher, Gregory R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Therapeutic Potential for Targeting Autophagy in ER plus Breast Cancer
    Finnegan, Ryan M.
    Elshazly, Ahmed M.
    Schoenlein, Patricia, V
    Gewirtz, David A.
    CANCERS, 2022, 14 (17)
  • [30] The tumor microbiome of ER plus versus triple-negative breast cancer.
    Noguti, Juliana
    Chan, Alfred A.
    Navarrete, Marian
    Lee, Delphine J.
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 66 - 67
12345